Outcome of conservative treatment and subsequent assisted reproductive technology for patients with early-stage endometrial adenocarcinoma and poor fertility potential.
- Author:
Xiao-Mei TONG
1
;
Hai-Yan ZHU
;
Xiao-Na LIN
;
Ling-Ying JIANG
;
Wei-Hai XU
;
Liu LIU
;
Song-Ying ZHANG
Author Information
1. Assisted Reproduction Unit, Department of Obstetrics and Gynecology, Sir Run Run Shaw Hospital, Zhejiang University, Zhejiang, Hangzhou, Zhejiang 310016, China.
- Publication Type:Case Reports
- MeSH:
Adenocarcinoma;
drug therapy;
metabolism;
Adult;
Antineoplastic Agents, Hormonal;
Endometrial Neoplasms;
drug therapy;
metabolism;
Female;
Follicle Stimulating Hormone;
therapeutic use;
Gonadotropins;
therapeutic use;
Humans;
Infertility;
Pregnancy;
Progesterone;
therapeutic use;
Reproductive Techniques, Assisted
- From:
Chinese Medical Journal
2012;125(19):3578-3580
- CountryChina
- Language:English
-
Abstract:
Conservative treatment with high doses of progestin is an alternative to standard hysterectomy for young patients with early-stage endometrial adenocarcinoma who desire to preserve their fertility. Here we report a patient with well-differentiated early-stage endometrial adenocarcinoma and poor fertility potential who failed to become pregnant in two in vitro fertilization-embryo transfer cycles and suffered a relapse after conservative treatment. This case illustrates that assessment of fertility potential is critical at the time of initial evaluation and conservative treatment planning for patients with endometrial adenocarcinoma.
